NF PROTOCOL 108, A Phase II Study of Binimetinib in Children and Adults with NF1 associated Plexiform Neurofibromas (PNOC010)
Study ID: STU 032018-010
This phase ii open label study will evaluate children [GreaterThanorequalTo] 1 year of age and adults with neurofibromatosis type-1 (nF1) and plexiform neurofibromas treated with the MeK inhibitor binimetinib. The primary aim of the study will be to assess quantitative radiographic response in a target lesion.
Primary objective: To determine the proportion of children and adults with nF1 associated plexiform neurofibromas who will have an objective response to binimetinib defined as a 20% or greater decrease in tumor volume reduction by 12 courses.